glp-1 alternatives to ozempic NotCo Uses AI Create Booster As 'Natural Alternative' OZEMPIC: Risks, Benefits, and Natural

Additionally, technological advancements in drug delivery and expanding indications for younger populations are contributing to market expansion

doi: 10.1126/scitranslmed.aat3392 [DOI] [PubMed] [Google Scholar] 69

Similarly, Lincoff et al59 conducted an RCT enrolling 17,604 patients aged 45 years or older with pre-existing cardiovascular disease and a BMI of 27 or higher but without a history of diabetes

What they're saying: "As the accessibility of these medications continues to rise and patient uptake increases, its crucial that we understand the neural mechanisms underlying the effects were seeing," Lorenzo Leggio, the clinical director of NIHs National Institute on Drug Abuse, said in a statement

The growing diabetes population creates a greater target market for GLP-1 receptor agonists